Red cell distribution width, other hematological parameters and atherogenic index of plasma in patients with clopidogrel and aspirin resistance

Yasemin Ustundag Budak¹, Kagan Huysal¹, Sanem Karadag Gege³, Hasan Ari³, Mehmet Melek³, Senol Yavuz¹, Sencer Came³, Alper Karakus³, Ibrahim Aktaş³, Selma Ari³

¹Department of Clinical Laboratory, University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
²Department of Microbiology, University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
³Department of Cardiology, University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
4Department of Cardiovascular Surgery, University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey

ABSTRACT

Objectives. Chronic inflammation might favour platelet hyperactivity, which leads to inter-individual variability in antiplatelet resistance. The aim of this study was to test the hypothesis that there is a relationship between some hematological parameters reported as measures of systemic inflammation, the atherogenic index of plasma (AIP), and antiplatelet responsiveness. Methods. This retrospective study included patients receiving aspirin (100 mg) and clopidogrel (75 mg) daily before and after stenting. Platelet inhibition was assessed using the VerifyNow P2Y12 point-of-care test. Resistance to antiplatelet therapy was defined as P2Y12 reactivity exceeding 240 units (for clopidogrel) or aspirin reaction units exceeding 550 units (for aspirin). The AIP was calculated as the logarithm of triglyceride/high density lipoprotein cholesterol. The white blood cell (WBC), platelet (P), neutrophil (N), and lymphocyte (L) counts, red cell distribution width (RDW), hemoglobin (Hb), plateletcrit, mean platelet volume (MPV), platelet distribution width, and N/L and P/L ratios were evaluated. Results. Of 232 patients (73% male; median age, 63 years; range, 38-87 years), 52 (22%) were aspirin resistant and 82 (35%) were clopidogrel resistant; 7.7% were both aspirin and clopidogrel resistant. Median RDW levels were significantly higher (14.4% [interquartile rate (IQR) 3] vs. 13.9% [IQR 1.3]; \(p=0.01\)) and Hb levels significantly lower (12.0±1.6 g/dL vs. 13.2±1.7 g/dL; \(p<0.001\)) in the clopidogrel-resistant patients than in the clopidogrel responders. WBC, AIP, MPV, N/L, and P/L ratios were not statistically significant (\(p>0.05\)). Multivariate logistic regression showed that Hb (odds ratio [OR]=0.73; 95% confidence interval [CI], 0.60-0.88; \(p=0.001\)) and RDW (OR=1.26; 95% CI, 1.02-1.55; \(p=0.02\)) were independent predictors of clopidogrel resistance. Conclusions. Both RDW and Hb were independent variables associated with clopidogrel resistance, but antiplatelet resistance cannot be predicted based on other hematological parameters or AIP.

Eur Res J 2016;2(3):200-205

Keywords: Red cell distribution width; hematological parameters; atherogenic index of plasma; systemic inflammation; clopidogrel resistance

Address for correspondence:
Yasemin Ustundag Budak, M.D., University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Department of Clinical Laboratory, Bursa, Turkey. E-mail: yaseminbudak2000@yahoo.com

Received: August 28, 2016; Accepted: October 7, 2016; Published Online: October 10, 2016

Copyright © 2016 by The Association of Health Research & Strategy

200
Introduction

Antiplatelet therapy is mandatory during and after percutaneous coronary intervention (PCI) for the prevention of acute stent thrombosis. To reduce the risk of stent thrombosis, dual antiplatelet therapy is currently recommended for PCI patients [1]. Stent thrombosis is more frequent when platelet inhibition by aspirin and clopidogrel is inadequate [2]. Clopidogrel and aspirin use different pathways to inhibit platelet aggregation. A combination of these drugs provides an additive effect over those of either agent alone [3]. There is wide inter-individual variability in the inhibitory effect of these drugs on platelet aggregation, some individuals exhibit a reduced or even absent antiplatelet response, and this is called antiplatelet drug resistance.

Inflammation and haemostasis are pathophysiologic processes that affect each other. Platelets influence various aspects of the inflammatory process, including interactions with leucocytes and the vascular endothelium. Recently, a number of studies have shown that chronic inflammation might favour platelet hyperactivity, which leads to inter-individual variability in antiplatelet resistance [4-6].

Mean platelet volume (MPV), platelet distribution width (PDW), neutrophil-to-lymphocyte (N/L) ratio are simple markers that indicate chronic inflammation [7]. The platelet-to-lymphocyte (P/L) ratio is an indicator of the balance between inflammation and thrombosis which is more advantageous than platelet or lymphocyte counts alone.

The atherogenic index of plasma (AIP) calculated as log triglyceride (TG)/high density lipoprotein cholesterol (HDL-C) has been universally used by practitioners as a significant predictor of atherosclerosis [8]. Plasma TG and HDL-C are basically opposite in direction with respect to measures of oxidative stress/systemic low-grade inflammation. Recently its shown that hypertriglyceridemia affects antiplatelet response [9].

We aimed to test the hypothesis that there is a relationship between inflammation-related haematological parameters, AIP and antiplatelet resistance. We also evaluated the relationship between RDW, MPV, N/L ratio, and P/L ratio, and (AIP) and antiplatelet responsiveness.

Methods

This study complies with the Declaration of Helsinki. The study protocol was approved by the Institutional Ethics Committee. This retrospective analysis was based on computerized databases in our Hospital’s cardiovascular center. All study participants were hospitalized as acute coronary patients from the emergency department and were scheduled to undergo planned PCI for other coronary vessels. In addition, all patients were undergoing elective PCI, and all medical records for the cases from January to December 2015 were reviewed.

Based on medical records, patients aged >18 years and receiving 75 mg daily doses of clopidogrel, combined with 100 mg aspirin daily during 10 days to one month prior to elective PCI, were selected. Peripheral venous blood samples were obtained from subjects prior to the next dose of clopidogrel and aspirin on elective PCI day for study.

Patients with severe anaemia, thrombocytopenia, myelodysplastic syndrome, coagulopathy and recent blood transfusion, history of stroke or central nervous system damage, recent major surgery, or chronic renal insufficiency requiring dialysis were excluded. Throughout the study, the quality of test results was validated by daily internal quality control procedures and participation in an external quality assessment scheme.

Platelet Aggregation Assays

Platelet response to aspirin and clopidogrel (P2Y12) was performed with the Verifynow point-of-care system (Accumetrics Inc., San Diego, CA) based on turbidimetric-based optical changes measurement in whole blood as platelets aggregate. Specific cartridges for the aspirin and P2Y12 pathway were used, and the degree of aggregation was quantified by a corresponding increase in light transmission and is reported as aspirin reaction units (ARU) and P2Y12 reaction units (PRU), respectively. In the literature, a value of ≥550 ARU indicates aspirin resistance, and clopidogrel resistance is indicated as PRU ≥240 [10].

Atherogenic Index

The levels of total cholesterol (T Chol), TG and HDL-C were determined using commercially available assay kits (Abbott Diagnostics, Abbott Park, IL) with an Architec C16000 auto-analyser (Abbott Diagnostics). AIP is calculated as previously described [8].
Complete Blood Cell Count
Samples were analysed in an automated haematology analysis system (Coulter LH-780 haematology analyser, Beckman Coulter Inc., Fullerton, CA) that measures platelet size and platelet count using aperture-impedance technology. The WBC, P, N and L counts, RDW, MPV and PDW were recorded, and the N/L and P/L ratios were calculated from these parameters. Patients with elevated WBC counts (>11,000/mL) and any inflammatory, infective, or malignant diseases were excluded from the study.

Statistical Analysis
Statistical analysis was performed using the Statistical Package for Social Sciences version 21.0 for Windows (SPSS Inc., Chicago, IL). Data are expressed as median (interquartile range) or mean±SD after normality test. The Shapiro–Wilk test was used to determine the normality of the evaluated variables. After evaluating the normality, statistically significant differences between parameters with Gaussian distributions were tested by a Student’s t-test; variables with a non-Gaussian distribution were compared using the Mann-Whitney U test. Variables (PRU, ARU, T Chol, N/L and P/L ratios, MPV, RDW were evaluated using the Spearman correlation coefficients. Logistic regression analysis of the relationship between clopidogrel resistance and the variables were analysed. Statistical significance was set at $p<0.05$.

Results
A total of 232 patients (73% male, median age, 63 years) were included in the analysis. The patients were divided into two groups according to aspirin and clopidogrel response. According to our criteria, a total of 52 patients (22%) were aspirin-resistant and 82 patients (35%) were clopidogrel-resistant (Tables 1 and 2). Approximately 7.7% of the patients were both aspirin-resistant and clopidogrel-resistant.

The median ARU for the responder group was 471 (interquartile range [IQR] 80), and 590 ARU (IQR 72) for aspirin-resistants. The median PRU for the responder group was 173 (IQR 100), and for the resistant group, it was 289 (IQR 46).

Median RDW levels were significantly higher (14.4% [interquartile rate [IQR] 3] vs. 13.9% [IQR 1.3]; $p=0.01$) and Hb levels significantly lower (12.0±1.6 g/dL vs. 13.2±1.7 g/dL; $p<0.001$) in the clopidogrel-resistant patients than in the clopidogrel responders. However; WBC, AIP, MPV, N/L, and P/L ratios were not statistically significant ($p>0.05$). Our correlation analysis indicated that clopidogrel resistance as PRU was positively correlated with

| Table 1. Demographic and laboratory parameters in patients (n=232) |
|---|---|---|---|
| Parameters | Aspirin responder | Aspirin resistant | $p$ |
| Age | 63 (15) | 64 (12) | |
| Number of patients | 180 | 52 | |
| Female/male | 43/137 | 20/32 | |
| Baseline laboratory results | | | |
| PRU | 206 (125) | 219 (187) | |
| ARU | 471(80) | 590(72) | |
| Hb (g/dL) | 12.7±1.9 | 13.0±1.4 | 0.831 |
| RDW (%) | 14.2 (1.6) | 14.0 (1.1) | 0.078 |
| Platelet $(10^3 /\mu L)$ | 235 (88) | 241 (80) | 0.451 |
| MPV (fL) | 8.6±1.0 | 8.3±1.0 | 0.089 |
| PCT | 0.20±0.06 | 0.20±0.04 | 0.706 |
| PDW (%) | 16.8±0.6 | 16.7±0.6 | 0.290 |
| WBC $(10^9 /\mu L)$ | 8.5(2.8) | 8.2(2.4) | 0.235 |
| N/L ratio | 2.6±1.4 | 2.5±1.4 | 0.299 |
| P/L ratio | 117±48 | 120±48 | 0.418 |
| T Chol (mg/dL) | 182±48 | 200±49 | 0.062 |
| Triglycerides (mg/dL) | 145 (107) | 162 (140) | 0.287 |
| HDL (mg/dL) | 40 (12) | 43 (14) | 0.591 |
| LDL (mg/dL) | 104±39 | 118±41 | 0.055 |
| Atherogenic index | 0.16±0.30 | 0.21±0.30 | 0.362 |

Data are expressed as median (interquartile range) or mean±SD after normality test. PRU=P2Y12 reactivity unit, ARU=aspirin reaction units, N/L=neutrophile/lymphocyte, P/L=platelet/lymphocyte, MPV=mean platelet volume, PCT=plateletcrit, PDW=platelet distribution width, WBC=white blood cell, T Chol=total cholesterol, HDL=high density lipoprotein, LDL=low density lipoprotein LDL.
RDW (r=0.297, p<0.001), and that aspirin resistance as ARU was negatively correlated with RDW (r= –0.149, p=0.023); whereas r values point to a poor correlation between variables. Hb was negatively correlated with PRU (r= –0.35, p<0.001) and RDW (r= –0.41, p<0.001). None of the other correlations were statistically significant (Table 3).

In univariate logistic regression analysis; Hb, RDW, and WBC were predictors of clopidogrel resistance (Table 3). In multivariate logistic regression analysis, Hb (odds ratio [OR]=0.73; 95% confidence interval [CI], 0.60-0.88; p=0.001) and RDW (OR=1.26; 95% CI, 1.02-1.55; p=0.02) were independent predictors of clopidogrel resistance (Table 4). None of the variables we evaluated was a risk factor for aspirin resistance.

### Discussion

This is the first study showing that high RDW is a significant and independent predictor of resistance to clopidogrel and that there is a negative correlation between RDW and PRU.

There are a number of studies indicating that RDW has been influenced by inflammation and oxidative stress, and a strong correlation between RDW and inflammatory markers, C-reactive protein, and sedimentation rate has been observed [11-13]. We found that inflammation-related CBC parameters were similar between the groups; however, this was not in agreement with our working hypothesis. We did not find a correlation between RDW and inflammation markers, N and WBC counts, N/L ratio, or MPV.
Oxidative stress may be another underlying biological mechanism that may lead to increased RDW. High oxidative stress contributes to elevated RDW by reducing RBC survival, increasing the release of large premature red blood cells into the peripheral circulation and increasing the fragility of red blood cells and affecting red cell lifespan [14]. Oxidative stress can enhance platelet aggregation to clopidogrel responsiveness in coronary artery disease patients [15]. Moreover, a recent study showed that patients under clopidogrel therapy showed different expressions of proteins involved in oxidative stress [16]. Because we did not look at the oxidative parameters, we cannot comment on if the RDW is related to the oxidant status in clopidogrel-resistants in our study group.

Tziakas et al. [17] described a link between RDW and lipidic composition of erythrocyte membranes. The stability of erythrocytes may be maximal within an optimal range of membrane fluidity [18]. Increases in erythrocyte membrane cholesterol levels are responsible for the deterioration of cell deformability, which affects the lifespans of circulating erythrocytes, and this results in elevated RDW values [13, 17, 18]. However, we did not find a correlation between AIP, T cholesterol, and RDW in our patients, which is in agreement with Vaya et al. [13]'s study. They also did not observe a correlation between RDW and T cholesterol, HDL-C, LDL cholesterol, or TG in a healthy Mediterranean population [13]. They found that RDW is associated with inflammatory markers but not with an unfavourable lipid profile.

Aspirin’s effect on platelet aggregation is subject to inter-individual and intra-individual variability, which can be attributed to multifactorial reasons [20-22]. MPV, PDW, or PCT values were not different between groups, similar to Nada [21]'s study, which observed that diabetic patients receiving aspirin or clopidogrel did not show significant differences in MPV when compared with controls [19]. Hyperglycaemia may decrease the effectiveness of antiplatelet therapy by increasing reactive oxidant species and lead to aspirin resistance by binding to thromboxane receptors, whereas hypercholesterolaemia may blunt aspirin's effect on thrombin [23, 24]. Genetics also play a role in patient response to aspirin as polymorphisms of platelets membranes postulated to cause aspirin resistance. However, we could not find the variables we evaluated as a risk factor of ASA resistance.

**The Limitations of the Study**

There are some limitations of this study. First of all, this is a single-centre, retrospective case-control study in which the selected population may not reflect the whole cohort. A lack of CRP, erythrocyte sedimentation rate and interleukin levels as inflammatory markers is another limitation of this study. Finally, we selected the VerifyNow method for ASA and clopidogrel resistance measurements, but there are other methods of measuring antiplatelet resistance that were not chosen for this study.

**Conclusions**

Antiplatelet resistance cannot be predicted based on other haematological parameters or AIP. However, this result should be verified in well-designed, large-scale studies on antiplatelet therapy resistance.

**Conflict of interest**

The authors disclosed no conflict of interest during
the preparation or publication of this manuscript.

Financing

The authors disclosed that they did not receive any grant during conduction or writing of this study.

References

[1] Wassef AW, Khafaji H, Syed I, Yan AT, Udell JA, Goodman SG, et al. Short duration vs standard duration of dual-antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: A systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials. J Invasive Cardiol 2016. pii: JIC2016915-2.

[2] Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, et al. Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J 2015;16:375-87.

[3] Manolis AS, Manolis TA, Papadimitriou P, Koulouris S, Melita H. Combined antiplatelet therapy: still a sweeping combination in cardiology. Cardiovasc Hematol Agents Med Chem 2013;11:136-67.

[4] Osmančík P, Paulu P, Tousek P, Kočka V, Vidimský P. High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. J Thromb Thrombolysis 2012;33:349-54.

[5] Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. Thromb Haemost 2013;109:920-9.

[6] Caruso R, Rocchiiccioli S, Gori AM, Cecchetti A, Giusti B, Parodi G, et al. Inflammatory and antioxidant pattern unbalance in "clopidogrel-resistant" patients during acute coronary syndrome. Mediators Inflamm 2015;2015:710123.

[7] Ozer S, Yılmaz R, Sonmezgoz E, Karaaslan E, Taskin S, Butun I, et al. Simple markers for subclinical inflammation in patients with Familial Mediterranean Fever. Med Sci Monit 2015;21:298-303.

[8] Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo B-lipoprotein-depleted plasma. Clin Biochem 2001;34:583-8.

[9] Karepov V, Tolpina G, Kuliczkowski W, Serebruany V. Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. Cerebrovasc Dis 2008;26:272-6.

[10] Song TJ, Suh SH, Min PK, Kim DJ, Kim BM, Heo JH, et al. The influence of anti-platelet resistance on the development of cerebral ischemic lesion after carotid artery stenting. Yonsei Med J 2013;54:288-94.

[11] Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: A simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci 2015;52:86-105.

[12] Fornal M, Wizner B, Cvynar M, Krolezyk J, Kwater A, Korbut RA, et al. Association of red blood cell distribution width, inflammation markers and morphological as well as rheological erythrocyte parameters with target organ damage in hypertension. Clin Hemorheol Microcirc 2014;56:325-35.

[13] Vaya A, Sarnago A, Fuster O, Alis R, Romagnoli M. Influence of inflammatory and lipidic parameters on red blood cell distribution width in a healthy population. Clin Hemorheol Microcirc 2015;59:379-85.

[14] Mohanty JG, Nagababu E, Rifkind JM. Red blood cell oxidative stress impairs oxygen delivery and induces red blood cell aging. Front Physiol 2014;5:84.

[15] Tresukosol D, Suktitipat B, Hunnangkul S, Kamkaew R, Poldee S, Tassaneentrithep B, et al. Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLoS One 2014;9:e110188.

[16] Volpi E, Giusti L, Ciregia F, Da Valle Y, Giannaccini G, Berti S, et al. Platelet proteome and clopidogrel response in patients with stable angina undergoing percutaneous coronary intervention. Clin Biochem 2012;45:758-65.

[17] Tziakas D, Chamakias G, Grapsa A, Gioka T, Tentes I, Konstantinides S. Red blood cell distribution width: a strong prognostic marker in cardiovascular disease: is associated with cholesterol content of erythrocyte membrane. Clin Hemorheol Microcirc 2012;51:243-54.

[18] de Freitas MV, de Oliveira MR, dos Santos DF, et al. Influence of the use of statin on the stability of erythrocyte membranes in multiple sclerosis. J Membr Biol 2010;233:127-34.

[19] Koter M, Franiak I, Strycharska K, Broncel M, Chojnowska-Jezierska J. Damage to the structure of erythrocyte plasma membranes in patients with type-2 hypercholesterolemia. Int J Biochem Cell Biol 2004;36:205-15.

[20] Lippi G, Sanchis-Gomar F, Danese E, Montagnana M. Association of red blood cell distribution width with plasma lipids in a general population of unselected outpatients. Kardiol Pol 2013;71:931-6.

[21] Nada AM. Red cell distribution width in type 2 diabetic patients. Diabetes Metab Syndr Obes 2015;30:525-33.

[22] Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 2004;43:1127-9.

[23] Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag 2013;5:965-72.